# Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents

**Authors:** Ferenc Dániel Petróczi, Angéla Tótik, Miklós Bege, József Király, Erzsébet Szabó, Zsuzsanna Szabó, Nikoletta Dobos, Rasha Ghanem Kattoub, Charu Upadhyay, Eszter Ostorházi, Jan Hodek, Jan Weber, József Arany, Dorottya Ádám, Christos C. Zouboulis, Attila Oláh, István Bajza, Árpád Tósaki, Gábor Halmos, Brijesh Rathi, Pál Herczegh, Anikó Borbás, Ilona Bereczki

PMC · DOI: 10.1186/s42238-026-00403-1 · 2026-02-05

## TL;DR

Researchers designed and tested fluorinated versions of CBD and CBG to improve their medical potential by enhancing their absorption and effectiveness.

## Contribution

The study introduces fluorinated derivatives of CBD and CBG that show improved pharmacokinetics and diverse therapeutic activities.

## Key findings

- Aliphatic fluorinated modifications improved absorption and pharmacokinetics compared to aromatic groups.
- Monosubstituted derivatives with aliphatic fluorine side chains, especially trifluoroethyl, were most promising.
- Some derivatives showed anticancer, antimalarial, and sebaceous lipogenesis-modulating effects.

## Abstract

Cannabidiol (CBD) and cannabigerol (CBG) are non-psychotropic phytocannabinoids that have significant, broad-spectrum therapeutic potential in a variety of pharmacological areas, but their unfavorable pharmacokinetics, such as extensive first-pass metabolism and low bioavailability, hinder their effective medical applications. Therefore, there is a great need for appropriate chemical modifications to improve their physicochemical properties. Incorporation of fluorine atom(s) at appropriate positions often improves the metabolic stability of the parent compound, increasing its bioavailability, and enhances its binding affinity to therapeutic targets, making fluorine a highly valuable element in modern drug development. Furthermore, amino functional groups may improve the water solubility and bioavailability of the compounds. Building on these principles, our strategy focused on introducing groups containing mono-, di-, and trifluoroethylamine or fluorinated aniline moieties into cannabinoids to improve their pharmacokinetic and pharmacological profiles.

Mannich-type reaction was applied, using commercially available 2-fluoroethylamine, 2,2-difluoroethylamine, 2,2,2-trifluoroethylamine, 3-fluoroaniline and 4-fluoroaniline as reagents. One or two oxazine rings with fluorine-containing side chains were condensed to the aromatic core of the cannabinoids, and the formation of mono- or disubstituted derivatives was controlled by the appropriate choice of reaction conditions. The biological activity of the derivatives was investigated in various relevant fields.

Our findings indicate that aliphatic modifications positively influence pharmacokinetic parameters, including absorption, in contrast to aromatic groups, which increase lipophilicity and lead to decreased bioavailability. Among the modifications, the monosubstituted derivatives containing a single oxazine ring with an aliphatic fluorine-containing side chain, especially the mono- and trifluoroethyl moieties, proved to be the most promising. These modifications appeared particularly advantageous in the CBG series compared to the properties of the CBG parent compound. This may suggest that the presence of a phenolic OH group is beneficial for biological activity. Some of the derivatives showed anticancer potential against various tumor cell lines, while others modulated sebaceous lipogenesis, and certain compounds exhibited a notable antimalarial effect.

The online version contains supplementary material available at 10.1186/s42238-026-00403-1.

## Linked entities

- **Chemicals:** Cannabidiol (PubChem CID 644019), CBD (PubChem CID 644019), Cannabigerol (PubChem CID 5315659), CBG (PubChem CID 5315659), 2-fluoroethylamine (PubChem CID 9996), 2,2-difluoroethylamine (PubChem CID 136274), 2,2,2-trifluoroethylamine (PubChem CID 9773), 3-fluoroaniline (PubChem CID 9742), 4-fluoroaniline (PubChem CID 9731)

## Full-text entities

- **Diseases:** tumor (MESH:D009369)
- **Chemicals:** aniline (MESH:C023650), 2,2,2-trifluoroethylamine (-), CBD (MESH:D002185), oxazine (MESH:D010078), cannabinoids (MESH:D002186), 3-fluoroaniline (MESH:C079598), water (MESH:D014867), 2-fluoroethylamine (MESH:C533396), CBG (MESH:C037036), 4-fluoroaniline (MESH:C043455), trifluoroethylamine (MESH:C032626), fluorine (MESH:D005461)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12964675/full.md

---
Source: https://tomesphere.com/paper/PMC12964675